Form 4: Allogene Therapeutics Director Deborah M. Messemer Reports Stock Acquisition and Disposal
SEC Form 4
Director Deborah M. Messemer reports acquiring and disposing of Allogene Therapeutics (ALLO) common stock on June 5, 2024.
Summary
- On June 5, 2024, Deborah M. Messemer, a director of Allogene Therapeutics, acquired 122,950 shares of common stock.
- On the same day, Messemer disposed of 185,406 shares of common stock.
- Following these transactions, Messemer beneficially owns 185,406 shares of Allogene Therapeutics.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting stock transactions by a company director. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It allows investors to monitor the actions of company directors and officers.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of stock acquisition and disposal. |
| 06/07/2024 | Date of signature on the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.